Standardized prenatal summary information was abstracted onto standard case report forms. with preexisting seroimmunity is secondary to virus reactivation or infection with a new or different CMV strain (reinfection) during Molibresib besylate pregnancy. We undertook a prospective study to determine the frequency of CMV reinfections in healthy seropositive women and to understand the various factors associated with such reinfections. Serial serum specimens from the study women were analyzed for strain-specific IgG antibodies against the polymorphic determinants on the envelope glycoproteins gH and gB of CMV using an ELISA method [3,8]. == Methods == Of the 258 CMV IgG seropositive postpartum women enrolled in the study between February 2000 and June 2004, 205 participants had serum samples from at least two visits, and these women constituted the study population. A standardized interview was administered at baseline to obtain demographic characteristics and exposure factors. Standardized prenatal summary information was abstracted onto standard case report forms. The study participants were followed at six-month intervals for up to three years and at each visit, serum samples were obtained and a standard questionnaire was administered to obtain an interval history of STIs, sex partner information, and caring for children. Serum specimens obtained at each visit were stored at -20C until analysis. The study was approved by the University of Alabama at Birmingham Institutional Review Board for Human Use, and informed consent was obtained from the participants prior to study enrollment. CMV strain-specific antibody responses were determined Rabbit Polyclonal to NF-kappaB p105/p50 (phospho-Ser893) based on polymorphisms in antibody binding sites within envelope glycoproteins, gH and gB, between the two prototypic laboratory strains of CMV, AD169 and Towne [8-10]. The detection of new antibody specificities to either epitope (AD169 or Towne) on gH or gB in follow-up serum samples was considered evidence of infection with a new virus strain (reinfection) during the study. One of the 258 women had antibodies to all four antigens at enrolment in the study and was excluded from the analysis. To approximate the average time to reinfection with a new virus strain from study entry, we measured the time from the baseline study visit until the visit during which new antibody specificities were detected. Recombinant peptides containing antibody combining sites within the amino terminal regions of gH and gB genes present in AD169 and Towne strains of CMV were synthesized and used as antigens to determine strain-specific IgG reactivity as described previously [3,8]. Strain-specific antibodies against the polymorphic gH and gB regions of CMV were determined using an ELISA method that has been validated in a recent report [8]. The demographic and exposure characteristics were compared between the groups of women with and without CMV reinfection. Statistical significance was determined using Chi-square, Fisher exact or Wilcoxon rank-sum test where appropriate. Univariate odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using the exact method. Multivariate unconditional logistic regression using backward stepwise selection with P<0.10 was used as a cutoff for retention in the model to assess whether exposure factors were associated with CMV reinfection. All data analyses were performed using SAS Molibresib besylate 9.1 software (SAS Institute, Inc, Cary, NC). == Results == The demographic characteristics of women with CMV reinfection were not different from those without evidence of reinfection. Both groups were predominantly single, Molibresib besylate African American ladies and experienced one previous pregnancy. The mean age for the study women in both organizations was 18 years and the study participants on average experienced 11 years of education. None of them of the study participants were HIV positive. Twenty-nine percent (59/205) of study ladies acquired fresh antibody specificities against gH or gB.